Drug
FOLFOX Regimen
CI-DRUG-00000240Explore in graph →NCIt C11197 CIViC
Regulatory
Approvals (0)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
Data not yet available
No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.
What CancerIndex knows
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Phase3 | Phase 3 | 53 | 34 | 40 | 162 | 0 | — | — | 1998-01 |
| Malignant Rectal Neoplasm | Phase3 | Phase 3 | 9 | 3 | 2 | 15 | 0 | — | — | 2004-12 |
| Malignant Gastric Neoplasm | Phase3 | Phase 3 | 5 | 4 | 1 | 15 | 0 | — | — | 2000-02 |
| Malignant Liver Neoplasm | Phase3 | Phase 3 | 5 | 3 | 4 | 12 | 0 | — | — | Mar 1, 2017 |
| Malignant Pancreatic Neoplasm | Phase3 | Phase 3 | 2 | 2 | 2 | 11 | 0 | — |
Curated evidence
Clinical evidence (1)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 19922504
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| GSTP1 I105V1 | ||||||||
| FOLFOX Regimen | Malignant Colorectal Neoplasm | |||||||
Clinical trials
Trials with this intervention (163)
Most recently updated first, 50 per page.
clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05482893 | Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | recruiting | Phase 1 / Phase 2 | 350 | Phanes TherapeuticsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05712356 | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors |